FDA warned Phoenix Nutritionals that disease-treatment claims on its supplement websites make eight products unapproved drugs, including COVID-19 claims.
What happened
FDA found this through a website review in June 2021, including phoenixvitamins.com, healthyinformation.com, and a Facebook page. It found orders for eight supplements and claims that they treat or prevent diseases such as cancer, diabetes, heart disease, arthritis, and COVID-19. FDA says these claims make the products drugs that require FDA approval and that the products lack adequate directions for safe use.
What FDA found
The products are drugs because the website claims say they cure, mitigate, treat, or prevent disease.
section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]The products are unapproved new drugs because they are not generally recognized as safe and effective for those uses and lack FDA approval.
section 201(p) [21 U.S.C. 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]The products are misbranded because they lack adequate directions for a layperson to use them safely for their intended uses.
section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5The products are intended for diseases that are not amenable to self-diagnosis or treatment without a licensed practitioner, so adequate directions cannot be written.
section 502(f)(1) [21 U.S.C. 352(f)(1)]Introducing or delivering these misbranded drugs into interstate commerce violates the Act.
section 301(a) [21 U.S.C. 331(a)]
What FDA wants
FDA asks the company to notify it in writing within 15 working days of steps taken to address the violations and prevent recurrence, with supporting documents. If corrective actions cannot be completed in that time, the company must explain the delay and give a completion date; if it disagrees, it must give its reasoning.
Who should pay attention
- supplement brands and online sellers that make disease claims
- retailers and distributors of vitamin and supplement products
- companies making COVID-19-related health claims
This is a summary. Read the original letter on fda.gov.